Literature DB >> 16968409

Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos.

D Grcević1, I K Lukić, N Kovacić, S Ivcević, V Katavić, A Marusić.   

Abstract

Activated T lymphocytes either stimulate or inhibit osteoclastogenesis from haematopoietic progenitors in different experimental models. To address this controversy, we used several modes of T lymphocyte activation in osteoclast differentiation--mitogen-pulse, anti-CD3/CD28 stimulation and in vivo and in vitro alloactivation. Osteoclast-like cells were generated from non-adherent immature haematopoietic monocyte/macrophage progenitors in murine bone-marrow in the presence of receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) and monocyte-macrophage colony-stimulating factor (M-CSF). All modes of in vivo and in vitro T lymphocyte activation and both CD4(+) and CD8(+) subpopulations produced similar inhibitory effects on osteoclastogenesis paralleled by enhanced dendritic cell (DC) differentiation. Osteoclast-inhibitory effect was associated with T lymphocyte activation and not proliferation, and could be replaced by their culture supernatants. The stage of osteoclast differentiation was crucial for the inhibitory action of activated T lymphocytes on osteoclastogenesis, because the suppressive effect was visible only on early osteoclast progenitors but not on committed osteoclasts. Inhibition was associated specifically with increased granulocyte-macrophage colony-stimulating factor (GM-CSF) expression by the mechanism of progenitor commitment toward lineages other than osteoclast because activated T lymphocytes down-regulated RANK, CD115, c-Fos and calcitonin receptor expression, and increased differentiation towards CD11c-positive DC. An activated T lymphocyte inhibitory role in osteoclastogenesis, confirmed in vitro and in vivo, mediated through GM-CSF release, may be used to counteract activated bone resorption mediated by T lymphocyte-derived cytokines in inflammatory and immune disorders. We also demonstrated the importance of alloactivation in osteoclast differentiation and the ability of cyclosporin A to abrogate T lymphocyte inhibition of osteoclastogenesis, thereby confirming the functional link between alloreaction and bone metabolism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16968409      PMCID: PMC1809724          DOI: 10.1111/j.1365-2249.2006.03181.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

Review 2.  Signals for activation of the GM-CSF promoter and enhancer in T cells.

Authors:  M F Shannon; L S Coles; M A Vadas; P N Cockerill
Journal:  Crit Rev Immunol       Date:  1997       Impact factor: 2.214

3.  Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor.

Authors:  N J Horwood; N Udagawa; J Elliott; D Grail; H Okamura; M Kurimoto; A R Dunn; T Martin; M T Gillespie
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

4.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

5.  Resting T cells negatively regulate osteoclast generation from peripheral blood monocytes.

Authors:  K Shinoda; E Sugiyama; H Taki; S Harada; T Mino; M Maruyama; M Kobayashi
Journal:  Bone       Date:  2003-10       Impact factor: 4.398

Review 6.  Osteoclasts, mononuclear phagocytes, and c-Fos: new insight into osteoimmunology.

Authors:  Koichi Matsuo; Neelanjan Ray
Journal:  Keio J Med       Date:  2004-06

7.  Kinetics of cytokine gene expression in human CD4+ and CD8+ T-lymphocyte subsets using quantitative real-time PCR.

Authors:  A O Abdalla; S Kiaii; L Hansson; E D Rossmann; M Jeddi-Tehrani; F Shokri; A Osterborg; H Mellstedt; H Rabbani
Journal:  Scand J Immunol       Date:  2003-12       Impact factor: 3.487

8.  c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling.

Authors:  A E Grigoriadis; Z Q Wang; M G Cecchini; W Hofstetter; R Felix; H A Fleisch; E F Wagner
Journal:  Science       Date:  1994-10-21       Impact factor: 47.728

9.  Gene array identification of osteoclast genes: differential inhibition of osteoclastogenesis by cyclosporin A and granulocyte macrophage colony stimulating factor.

Authors:  Christopher J Day; Michael S Kim; Sébastien R J Stephens; Wendy E Simcock; Cathy J Aitken; Geoff C Nicholson; Nigel A Morrison
Journal:  J Cell Biochem       Date:  2004-02-01       Impact factor: 4.429

Review 10.  The mechanism of osteoclast differentiation from macrophages: possible roles of T lymphocytes in osteoclastogenesis.

Authors:  Nobuyuki Udagawa
Journal:  J Bone Miner Metab       Date:  2003       Impact factor: 2.626

View more
  16 in total

1.  Chemotactic and immunoregulatory properties of bone cells are modulated by endotoxin-stimulated lymphocytes.

Authors:  Hrvoje Cvija; Natasa Kovacic; Vedran Katavic; Sanja Ivcevic; Hector Leonardo Aguila; Ana Marusic; Danka Grcevic
Journal:  Inflammation       Date:  2012-10       Impact factor: 4.092

2.  Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors.

Authors:  Jinlu Dai; Yi Lu; Chunyan Yu; Jill M Keller; Atsushi Mizokami; Jian Zhang; Evan T Keller
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

Review 3.  The multiple faces of autoimmune-mediated bone loss.

Authors:  Georg Schett; Jean-Pierre David
Journal:  Nat Rev Endocrinol       Date:  2010-11-02       Impact factor: 43.330

Review 4.  The immune system and bone.

Authors:  Roberto Pacifici
Journal:  Arch Biochem Biophys       Date:  2010-06-17       Impact factor: 4.013

5.  Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis.

Authors:  Kalle Söderström; Emily Stein; Paula Colmenero; Ulrich Purath; Ulf Müller-Ladner; Cristina Teixeira de Matos; Ingo H Tarner; William H Robinson; Edgar G Engleman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

Review 6.  Targeting Fas in osteoresorptive disorders.

Authors:  Natasa Kovacic; Danka Grcevic; Vedran Katavic; Ivan Kresimir Lukic; Ana Marusic
Journal:  Expert Opin Ther Targets       Date:  2010-10       Impact factor: 6.902

7.  Interferon-γ Released by Activated CD8+ T Lymphocytes Impairs the Calcium Resorption Potential of Osteoclasts in Calcified Human Aortic Valves.

Authors:  Edit Nagy; Yang Lei; Eduardo Martínez-Martínez; Simon C Body; Florian Schlotter; Michael Creager; Alexander Assmann; Kamal Khabbaz; Peter Libby; Göran K Hansson; Elena Aikawa
Journal:  Am J Pathol       Date:  2017-04-19       Impact factor: 4.307

8.  TGF-β in dentin matrix extract induces osteoclastogenesis in vitro.

Authors:  Wannakorn Sriarj; Kazuhiro Aoki; Keiichi Ohya; Mariko Takahashi; Yuzo Takagi; Hitoyata Shimokawa
Journal:  Odontology       Date:  2013-12-24       Impact factor: 2.634

9.  Association of systemic and intra-articular osteoclastogenic potential, pro-inflammatory mediators and disease activity with the form of inflammatory arthritis.

Authors:  Marina Ikić; Zrinka Jajić; Elvira Lazić; Sanja Ivčević; Frane Grubišić; Ana Marušić; Nataša Kovačić; Danka Grčević
Journal:  Int Orthop       Date:  2013-10-08       Impact factor: 3.075

10.  Suppressive effects on the immune response and protective immunity to a JEV DNA vaccine by co-administration of a GM-CSF-expressing plasmid in mice.

Authors:  Hui Chen; Na Gao; Dongying Fan; Jiangman Wu; Junping Zhu; Jieqiong Li; Juan Wang; Yanlei Chen; Jing An
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.